Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such as Proteus,...
Urine Studies II: Urine Culture and Sensitivity Test01:26

Urine Studies II: Urine Culture and Sensitivity Test

A urine culture and sensitivity test is a diagnostic procedure used to identify urinary tract bacterial infections and determine the most effective antibiotics for treatment. This test is generally preferred when a patient shows manifestations of a urinary tract infection, such as frequent or painful urination, cloudy or foul-smelling urine, or lower abdominal pain.Purpose of the TestThe primary goals of a urine culture and sensitivity test are to:Determine the specific bacteria causing the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HydrOcortisone and fludRocortisoNe for critical ILLness-related corticosteroid insufficiency (HORNbILL): study protocol for a multicentre randomised placebo-controlled trial.

BMJ open·2026
Same author

Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).

Critical care medicine·2026
Same author

High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.

medRxiv : the preprint server for health sciences·2026
Same author

Rethinking fairness in unsupervised healthcare AI: A methodological scoping review.

Journal of biomedical informatics·2026
Same author

Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: A retrospective cohort study in France.

Journal of neuromuscular diseases·2026
Same author

Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Chagas Disease: An Opportunistic Infection in AIDS.

Current infectious disease reports·2026
Same journal

Area-based Deprivation Indices and Healthcare-Associated Infections: A Narrative Review of Evidence.

Current infectious disease reports·2025
Same journal

Next Steps: Studying Diabetic Foot Infections with Next-Generation Molecular Assays.

Current infectious disease reports·2024
Same journal

To Tweet or Not to Tweet-a Review of the Viral Power of Twitter for Infectious Diseases.

Current infectious disease reports·2024
Same journal

Web alert.

Current infectious disease reports·2024
Same journal

Bacterial Vaginosis in Postmenopausal Women.

Current infectious disease reports·2023
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

Cecal Ligation Puncture Procedure
11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

Adjunct therapy for sepsis: how early?

Djillali Annane1

  • 1General Intensive Care Unit, Raymond Poincaré hospital (AP-HP), University of Versailles SQY, 104 boulevard Raymond Poincaré, 92380, Garches, France, Djillali.annane@rpc.aphp.fr.

Current Infectious Disease Reports
|February 11, 2011
PubMed
Summary
This summary is machine-generated.

Sepsis management involves anti-infectives and supportive care. Adjunct therapies like activated protein C and hydrocortisone should be initiated within 24 hours for non-responsive patients.

More Related Videos

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies
07:34

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Published on: April 11, 2012

Related Experiment Videos

Last Updated: Jun 4, 2026

Cecal Ligation Puncture Procedure
11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies
07:34

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Published on: April 11, 2012

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Sepsis is a significant global cause of mortality.
  • Current management focuses on infection control and organ support.
  • Timely intervention is crucial for patient outcomes.

Purpose of the Study:

  • To outline the optimal management strategy for sepsis.
  • To define the role and timing of adjunct therapies in sepsis treatment.

Main Methods:

  • Review of current clinical guidelines and evidence for sepsis management.
  • Emphasis on the integration of anti-infective therapy, hemodynamic support, and oxygenation optimization.
  • Criteria for initiating adjunctive treatments.

Main Results:

  • Effective sepsis management requires prompt anti-infective treatment and supportive care.
  • Activated protein C and hydrocortisone are the sole approved adjunct therapies.
  • These adjuncts are recommended for patients not improving after 6 hours of optimal standard care, ideally initiated within 24 hours of shock onset.

Conclusions:

  • Early and comprehensive management is key to improving sepsis survival rates.
  • Adjunct therapies should be considered in specific patient populations based on response to initial treatment.
  • Adherence to treatment timing protocols can enhance therapeutic efficacy.